Search results
Showing 811 to 825 of 7690 results
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)
Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.
Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic kidney disease in adults.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)
Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.
Evidence-based recommendations on using coronary artery stents in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.